Condition: Von Willebrand Diseases · Sponsor: University of Washington
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding. This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
This description comes directly from the study's public registry record.
Central Study Contact · 919-792-3740 · VIP.Study@ergomedgroup.com
Always discuss trial participation with your own doctor first.
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Bleeding & Clotting Disorders Institute | Peoria, Illinois, United States | Recruiting |
| Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders | New Orleans, Louisiana, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Withdrawn |
| The Pennsylvania State University | Hershey, Pennsylvania, United States | Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Washington Center for Bleeding Disorders | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04146376